ROVI has commenced the marketing of its enoxaparin biosimilar in Spain


No votes yet
 
Related
Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) has reached an agreement with a subsidiary of MSD (“MSD”) whereby ROVI acquires certain...
2 min
15/02/2019
Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) has announced the purchase of Falithrom®, which was owned by Hexal AG (“Hexal”), a company...
1 min
09/01/2019
0 min
06/11/2018